Polysaccharide

DolCas Biotech demonstrates Curcugen® in chocolate at Vitafoods

Retrieved on: 
Martedì, Aprile 30, 2024
Capsule, Solubility, Polysaccharide, Health, Tablet, Food, Curcumin, Medicine, DMC, Drink, Absorption, Plasma

LANDING, N.J., April 30, 2024 /PRNewswire/ -- DolCas Biotech, LLC will introduce a new prototype of delicious chocolate laced with its flagship curcumin ingredient Curcugen® to demonstrate its versatility in functional foods and beverages. The tasty reveal will occur at the Vitafoods Europe in Geneva, booth #N217, May 14-16, 2024.

Key Points: 
  • "We bring functional chocolate to Switzerland—a country famous for its chocolate—to reinvent the chocolate segment with added better-for-you value," asserts Dr. Shavon Jackson-Michel, Director of Medical & Scientific Affairs for DolCas Biotech.
  • To tackle this, DolCas partnered with a boutique chocolate maker to create the perfect chocolate with all the sensory experience consumers crave.
  • The collaboration resulted in an indulgent chocolate bite enriched with Curcugen's anti-inflammatory and antioxidant benefits to suit consumers desiring innovative delivery systems for wellness ingredients.
  • The 2x2-inch chocolate square is individually wrapped for visitors at Vitafoods Europe to sample the fun, tasty treat.

ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M

Retrieved on: 
Mercoledì, Aprile 17, 2024
Combination, Safety, Ophthalmology, Oncology, Dietary supplement, Polysaccharide, Immunotherapy, Partnership, Research, IND, CNS, Non-small-cell lung cancer, MSKCC, Lung cancer, Grifola frondosa, Therapy, Patient, Combination therapy, Edible, Myelodysplastic syndrome, Health, Triple-negative breast cancer, Clinical trial, MDS, Ergosterol, TNBC, US FDA, Investigational New Drug, Virginity, Pharmaceutical industry

The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.

Key Points: 
  • The Investigational New Drug (IND) application for ABV-1519 proposed the clinical investigation of BLEX 404 as a Combination Therapy Drug with Chemotherapy.
  • We believe that this collaboration leverages the respective strengths of both companies to accelerate the availability of this vital treatment to patients worldwide.
  • This licensing agreement exemplifies ABVC and OncoX's shared dedication to advancing medical science and improving patient care.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts: visit https://abvcpharma.com/?page_id=17707

ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M

Retrieved on: 
Mercoledì, Aprile 10, 2024
Use, BioLite, Ophthalmology, Polysaccharide, Pancreatic cancer, License, Dietary supplement, Partnership, IND, CNS, Non-small-cell lung cancer, CDMO, Knowledge, Investigational New Drug, Therapy, Royalty payment, Field, Edible, Myelodysplastic syndrome, Triple-negative breast cancer, MDS, Ergosterol, NSCLC, TNBC, US FDA, Pharmaceutical industry

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • [1]
    "We are thrilled to announce that the term sheet for a potential groundbreaking licensing deal with OncoX has been successfully executed.
  • This licensing deal marks a significant milestone for ABVC and OncoX, affirming their commitment to excellence and shared vision for the future.
  • ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707

Global Biodegradable Microbeads Market Report 2024, with Profiles of Ajinomoto, Andritz, Asahi Kasei, BASF, Bioweg, CELLiCON, Croda, Daicel, Green Science, Lactips, LignoPure, Naturbeads and More - ResearchAndMarkets.com

Retrieved on: 
Lunedì, Aprile 1, 2024
Cosmetics, Retail, Chemicals, Plastics, Oil, Gas, Manufacturing, Energy, Polysaccharide, Microplastics, BASF, Market, Asahi Kasei, Health, Agriculture, Research, Classification, Polyester, Food, Detergent, Protein, Skin, Drink, USD

The "Global Market for Biodegradable Microbeads 2024-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Biodegradable Microbeads 2024-2035" report has been added to ResearchAndMarkets.com's offering.
  • Plastic microbeads are a multi-billion dollar market, with applications in markets ranging from cosmetics to oil & gas.
  • Replacement of plastic microbeads with biodegradable and non-toxic alternatives is increasingly important and the market will grow to meet both regulatory demands and increased use of microbeads in healthcare (e.g.
  • Many companies have curtailed their use or pivoted to natural alternatives, but it still represents a sizeable global market.

TerraSafe Materials and Penn State Announce Licensing Agreement to Commercialize Breakthrough Material Technologies

Retrieved on: 
Martedì, Febbraio 27, 2024
Pennsylvania State University, Adhesive, Commercialization, Research, State College, Pennsylvania, Innovation Park, Research and development, Biological engineering, Polysaccharide, Food packaging, Wood, Building material, Starch, Hope, Food, Cellulose, BIV, State, GFRP, Microplastics, Ecosystem, Bioethics, Associate, Intellectual property, Agriculture, AG, PSU

TerraSafe is launching its first rural Research & Development facility at the Penn State Innovation Park, where the Company plans to run analytic testing for new material technologies in development.

Key Points: 
  • TerraSafe is launching its first rural Research & Development facility at the Penn State Innovation Park, where the Company plans to run analytic testing for new material technologies in development.
  • TerraSafe is leveraging intellectual property created by researchers at the Pennsylvania State University (“PSU”) in the biomaterials space.
  • “The support that this ecosystem can bring to startups like TerraSafe is why we located our first R&D center in State College.
  • The collaboration between TerraSafe and Penn State marks a major milestone of its core mission to build and grow companies throughout the rural United States.

ABVC's New Horizon for Oncology and Hematology Aims at Cancer Market of Several Hundred Billion Dollars

Retrieved on: 
Martedì, Febbraio 27, 2024
NSCLC, Therapy, Reflection nebula, Ophthalmology, Marketing, Investigational New Drug, Immune system, Myelodysplastic syndrome, Immunotherapy, Collateral damage, Shogun, FDA, Dietary supplement, US FDA, Polysaccharide, Nausea, Grifola frondosa, Hair loss, CDMO, Safety, MDS, Fatigue, CNS, TNBC, Edible, Ergosterol, Patient, Quality of life, Drug, Immunity, IND, Cancer

The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.

Key Points: 
  • The Investigational New Drug (IND) application proposed the clinical investigation of BLEX 404 as the primary active ingredient.
  • The global cancer therapeutics market is expected to be worth around US$ 393.61 billion by 2032 from US$ 164 billion in 2022, growing at a CAGR of 9.20% from 2023 to 2032.
  • [4] Straits Research reports that the global botanical drug market size was valued at $163 million in 2021 and is expected to be valued at $3.2 billion.
  • The market is expected to grow at a CAGR of 39% during the forecast period (2022–2030).

Going Beyond Plastic: Chung-Ang University Team Explores Tara Gum as a Green Polymer

Retrieved on: 
Martedì, Gennaio 16, 2024
Seed, Nanoparticle, Research, Toxicology, Food, Polysaccharide, D-3, Behavior, Administration, Plastic, Chung-Ang University, Edible, Zinc, Safety, Chitosan, Food industry, Copper, Carbohydrate Polymers, South Korea, Pollution, Gum arabic

SEOUL, South Korea, Jan. 16, 2024 /PRNewswire/ -- Synthetic, non-biodegradable plastics are major sources of environmental pollution and have prompted a rising interest in sustainable, biodegradable alternatives derived from natural polymers. "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution. This natural, water-soluble substance contains polysaccharides (complex carbohydrates), including the widely used "galactomannan," which is employed in coatings, edible films, and as a stabilizer and thickener. The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery. Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.

Key Points: 
  • "Tara gum," derived from the seeds of the tara tree (Caesalpinia spinosa), stands out as a promising solution.
  • The biocompatibility, biodegradability, and safety of tara gum also make it valuable in industries like food and drug delivery.
  • Moreover, the adaptable nature of the groups within tara gum polysaccharides renders it valuable for tailoring physicochemical and mechanical properties for specific applications.
  • "The physicochemical property of tara gum and its products can be enhanced using various kinds of monomers, crosslinkers, or other polysaccharides.

Hydrocolloidal Market to Reach $18.7 Billion, Globally, by 2032 at 5.6% CAGR: Allied Market Research

Retrieved on: 
Venerdì, Dicembre 8, 2023
Chart, Research, Consumer, Drink, Colloid, Phlorotannin, Urbanization, Lectin, Food, PDF, Polysaccharide, Biotechnology, Yogurt, Kainic acid, Ice cream, Cosmetics, Supply, Food industry, Table, Administration, Seaweed, Agent handling, Carrageenan, Transport, Restaurant, Pharmaceutical industry, Health, Sesquiterpene

PORTLAND, Ore., Dec. 8, 2023 /PRNewswire/ -- Allied Market Research published a report, titled, "Hydrocolloidal Market by Product Type (Seaweed and Others), Function (Thickening Agent, Gelling Agent, Stabilizing Agent, and Others), End-use Industry (Food & Beverage, Pharmaceutical, Cosmetics, and Others): Global Opportunity Analysis and Industry Forecast, 2023-2032". According to the report, the global hydrocolloidal industry generated $10.9 billion in 2022, and is anticipated to generate $18.7 billion by 2032, witnessing a CAGR of 5.6% from 2023 to 2032.

Key Points: 
  • Restrictions on transportation and lockdown measures in various regions affected the production and distribution of raw materials and finished products.
  • ·  Impact on End-Use Industries: The hydrocolloidal market serves various industries, including food and beverages, pharmaceuticals, and cosmetics.
  • For example, the closure of restaurants and disruptions in food service had implications for certain food applications of hydrocolloids.
  • This has led to changes in dietary habits, increased demand for processed foods, and subsequently, a growing market for hydrocolloids.

Lucius Partners Portfolio Company Voltron Therapeutics, Inc. Announces Completion of a Trial Protocol to Study its Self Assembling Vaccine to Target Prostate Stem Cell Antigen

Retrieved on: 
Lunedì, Novembre 20, 2023
Antigen, PSCA, SAV, Therapy, Polysaccharide, Peptide, Protein, Epitope, Prostate cancer, Vaccine, Infection, Cancer, Survival, Massachusetts General Hospital, T cell, Neoplasm, Checkpoint, HPV, Dicarboxylic acid, Inflammation, Hospital, Checkpoint inhibitor, Voltron

NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).

Key Points: 
  • NEW YORK, Nov. 20, 2023 /PRNewswire/ -- Voltron Therapeutics, Inc., a Lucius Partners portfolio company, today announced that it has finalized the protocol for a Dose-Ranging Efficacy Study of VTX-0P4, a protein-based cancer vaccine targeting Prostate Stem Cell Antigen (PSCA).
  • Voltron recently demonstrated immunogenicity against PSCA in a double blind pre-clinical trial conducted at the Vaccine and Immunotherapy Center at the Massachusetts General Hospital.
  • In that trial VTX-0P4 significantly augmented T-Cell responses when compared to controls against this important tumor target while, once again, exhibiting a very clean safety profile.
  • "We are excited to initiate Voltron's PSCA pre-clinical efficacy trial," said James Ahern, Managing Partner of Laidlaw & Company and co-founder of Lucius Partners.

Global Market for Bioplastics and Natural Fibers Report 2023-2033: Profiles of 500 Companies Including BASF, NatureWorks, Cathay, DuPont and Spiber - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Novembre 2, 2023
Chemicals, Plastics, Manufacturing, Textiles, Polylactic acid, Danimer Scientific, Government, United Building & Construction Trades Council v. Mayor and Council of Camden, PHA, Textile, Sport, Borealis, Mitsubishi Chemical Corporation, Carbon, Silk, Nature, AMSilk, MFC, Luffa, Protein, BASF, PBS, Bioplastic, Growth, NatureWorks, Renewable polyethylene, Polyethylene terephthalate, Food packaging, DuPont, Ecovative Design, Agriculture, Flax, Fiber crop, Polyhydroxyalkanoates, Cathay, Polysaccharide, Polyethylene

The "Global Market for Bioplastics and Natural Fibers 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Market for Bioplastics and Natural Fibers 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The bioplastics and natural fibers market will witness good growth through to 2033, with excellent opportunities for large producers and start-ups.
  • The report provides an in depth analysis of the bioplastics and natural fibers market by applications and bioplastic and natural fiber type.
  • Analysis of natural fibers including seed fibers (cotton, luffa), bast fibers (jute, hemp, flax, ramie, kenaf), leaf fibers (sisal, abaca).